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OBJECTIVES: Chronic spontaneous (or idiopathic) urticaria (CSU/CIU) affects 
approximately 0.6% of Taiwanese population. However, little is known about its 
economic impacts in the healthcare system. This study aims to examine the 
costs of CSU/CIU-related treatment in National Health Insurance (NHI) program 
of Taiwan. METHODS: Patients who had at least two outpatient visits (primary/
secondary ICD-9-CM diagnosis code of 708.1, 708.8 or 708.9) with antihistamine 
prescription and occurred at least 42 days apart during 2011 were considered as the 
CSU/CIU cases from the NHI Research database(NHIRD). The cases were matched 
with controls in a 1:4 ratio by age, gender and residential areas from the 2011 NHI 
claims data files for 1-million beneficiaries who were representative of the popula-
tion of Taiwan in 2005. Differences in costs associated with outpatient care, inpatient 
care, emergency care, medical tests and drugs between CSU/CIU cases and their 
comparison groups were predicted by the two-part models and the generalized lin-
ear models. All analysis was stratified by the severity level of CSU/CIU and all costs 
were reported in 2012 New Taiwan dollars (US$1 = NT$30). RESULTS: There were 
145,700 CSU/CIU patients identified as the study cases based on above algorithm, 
of which 83.96% were mild CSU/CIU (dCSU), 15.79% were moderate CSU/CIU (mCSU) 
and 0.25% were severe CSU/CIU (sCSU). The case-comparison analysis showed that 
the NHI costs for patients with dCSU, mCSU and sCSU was 1.23 times, 1.43 times, 
and 1.93 times the costs of the matched controls, respectively. The annual total 
costs attributed to dCSU, mCSU and sCSU were NT$5,730, NT$9,168 and NT$20,522, 
respectively. Costs associated with outpatient care comprised the largest proportion 
of total costs for dCSU patients (60.0%) and for mCSU patients (57.5%). As for sCSU 
patients, the largest components of costs were medical tests (35.0%) and drugs 
(39.4%). CONCLUSIONS: CSU/CIU has substantially impact on direct medical costs 
in Taiwan. The costs increase remarkably with the severity of disease.
PSS17
coSt of canalicular lacEration rEPair in diffErEnt hoSPital 
SEttingS: a dEciSion analySiS
Cannon-Dang E.1, Murchison A.P.2, Bilyk J.R.2, Pizzi L.T.1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Wills Eye Hospital, Philadelphia, PA, USA
OBJECTIVES: To calculate the costs of canalicular laceration (CL) repair at a tertiary 
academic eye care center based on setting and surgeon type. METHODS: A retro-
spective review of hospital records over a 10-year span of all primary CL repairs 
performed at a tertiary eye institution. Input variables included repair setting (minor 
procedure room; MPR vs. operating room; OR), surgeon type (oculoplastic surgeon, 
ophthalmologist, fellow, or resident), stent type (mini-Monoka vs. Crawford), and 
success rate (no epiphora/tearing down face, even with environmental stressors, 
at > 3 months after stent removal). Procedure-level data were used to inform prob-
abilities in a decision analytic model (TreeAge Pro). Costs inputs included supplies 
(institution acquisition prices for drugs and disposable equipment) and personnel 
(institution wages + 30% fringe benefits for surgeon, nurse, nurse anesthetist, anes-
thesiologist, and scheduler). Output of the model was cost per successful repair. 
Univariate sensitivity analyses were performed to test the impact of modifying 
base case inputs ± SD. RESULTS: The estimated cost per procedure was $US323 
in the MPR and $US589 in the OR. The overall success rate in the MPR was 37%, vs. 
88% in the OR (p< 0.0001). The ICER revealed the incremental cost of performing CL 
repair in the OR per success to be $521.56. Within each setting, cost effectiveness of 
oculoplastic surgeons dominated vs. the other surgeon types. Sensitivity analyses 
revealed OR costs to be most sensitive to nurse anesthetist and nurse time, whereas 
MPR costs were most sensitive to ophthalmologist and nurse time. CONCLUSIONS: 
While it was more costly to perform CL repair in the OR, success rates were much 
higher. In addition, success rates were optimal when performed by oculoplastic sur-
geons, suggesting that sub-specialty training maximizes patient outcome. Findings 
are limited to a single institution but call to question whether this procedure should 
be performed in a MPR.
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OBJECTIVES: The objective of this study is to evaluate the cost-effectiveness 
of aflibercept compared to ranibizumab and dexamethasone in the treatment 
of central retinal vein occlusion (CRVO) in Turkey. METHODS: A Markov model 
consisting of health states based on the number of letters read in 15 letter incre-
ments from legal blindness (< 35 letters) to 80+ letters with 30-year timeframe, 
was adapted to the Turkish local setting. Clinical inputs as transitions probabilities 
and incidences of adverse effects were mainly derived from the results of Phase 
III COPERNICUS and GALILEO trials. Economic inputs were based on the expert 
opinion addressing local treatment, monitoring and adverse event management 
algorithms. The primary endpoint was QALYs. Analyses were conducted from the 
Turkish Payer Social Security Institution perspective. All costs were calculated in 
Turkish Liras (TL) and converted to USD using TL/USD currency rate as 2,1 (mid-
2014). RESULTS: The total number of QALYs associated with aflibercept, ranibi-
zumab and dexamethasone were 17.926, 17.194 and 16.928 QALYs respectively; 
resulting in total of 0,101 and 0,368 more QALYs for the treatment with aflibercept 
OBJECTIVES: Equine recurrent uveitis (ERU) is the most common cause of blindness in 
horses world-wide. Several organisms have been associated with ERU, with leptospires 
being the most commonly reported agent. Irrespective of substantial treatment costs, 
the value of affected horses is progressively reduced as ocular involvements (unilateral 
or bilateral visual impairment or blindness) increase. This study aimed to estimate 
the number of horses affected by ERU in the U.S, and approximate the associated 
depreciation due to vision impairment. METHODS: The U.S. horse population size 
was estimated by market research. Published sources allowed the estimation of (1) the 
risk of ERU, (2) the associated visual impairments, accounting for breed differences, 
and (3) the loss of value in function of different ocular involvements and variable 
uses of a horse. Considering U.S. horse breeds and use distributions, the number of 
horses allocated to different levels of vision impairment and associated relative depre-
ciations were calculated. Average value of horses was derived from official sources, 
conservatively excluding very high-priced competition/race horses. RESULTS: It was 
estimated that 576,000 horses are currently affected by ERU in the U.S. Based on ret-
rospective studies, 198,513 and 104,269 of these horses are or are expected to become 
blind in one or both eyes during the next 11 years, respectively. From those horses being 
impaired but maintaining vision, 151,046 horses are unilaterally and 122,172 bilater-
ally affected. Depreciation in horses currently affected by ERU was conservatively 
calculated to $802,482,773. It was estimated that 70% of those losses are caused by 
leptospires. CONCLUSIONS: Approximately 576,000 horses are currently affected by 
ERU in the U.S., from which more than 300,000 horses will become blind in one or both 
eyes. ERU represents a substantial economic burden which conservatively calculates 
to more than $800 MM due to the loss of horse value, not considering treatment costs.
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OBJECTIVES: To estimate the cost of illness associated with diabetic macular edema 
(DME) in 13 countries, with a focus on diagnosis, treatment and cost of advanced 
disease. METHODS: A structured literature review to assess prevalence and cost of 
DME was conducted including Embase, Medline, government and professional asso-
ciation websites. Structured face-to-face or online interviews were conducted with 
378 ophthalmologists experienced in managing DME to determine rates of diagnosis, 
use of drug and laser treatments and frequency of follow-up and monitoring vis-
its. Countries were Belgium, Czech Republic, Finland, France, Germany, Ireland, the 
Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and China. An excel model 
synthesizing data and estimated overall cost of illness was built; costs were converted 
to Euros at 2014 market rates. RESULTS: Across the 13 countries an estimated 5.3 
million people have DME; physicians estimated 32-68% (range between countries) of 
DME patients are undiagnosed, a total of 3.1m people. Annual medical cost of DME 
was estimated to be € 1.2bn, median medical cost per patient was € 918, range from € 46 
(China) to € 4,858 (Switzerland). Productivity loss due to poor vision in DME patients 
costs € 4.7bn, 71% of the total cost of illness. Other cost components were laser and 
drug treatments (mean across countries 17.9%, range 1.4-38.9%), follow-up visits (5.8%, 
2.6-33.9%) and monitoring visits (2.9%, 0.3-15.9%). Diagnosis accounted for 0.3% of 
the total cost (range 0.1-0.9%). Some cost components could not be reliably estimated 
for all countries. CONCLUSIONS: Considerable variation was identified in screening, 
diagnosis and treatment between countries. Despite the availability of effective thera-
pies, physicians reported that current practice fails to identify a substantial proportion 
of patients with DME. Poor vision due to DME results in economic loss that is much 
larger than current spending on therapy. Limitations include use of expert opinion 
and incomplete data; results may not be generalizable outside the countries studied.
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OBJECTIVES: Describing the cost of care for glaucoma patients will lead to a better 
understanding of the disease impact on the healthcare system. Few studies have 
determined healthcare costs associated with glaucoma patients, and even fewer 
examined a commercially insured population. This study sought to characterize 
and compare the glaucoma specific costs and overall healthcare costs before and 
after diagnosis. METHODS: We analyzed a large US commercial claims database to 
identify patients 18 years and older with an initial diagnosis of open-angle glaucoma 
occurring in 2011. Patients with two separate occurrences of open-angle glaucoma 
codes (ICD-9 365.10 or 365.11) were included. Patients were excluded for presence 
of a glaucoma code in the 12 months before their initial diagnosis, other types of 
glaucoma (i.e. angle-closure glaucoma), or other possible causes of vision loss (i.e.: 
cataracts). Outcomes of interest were glaucoma specific and overall healthcare costs 
for the 12-months before (baseline) and 12-months after (follow-up) initial diagnosis. 
Costs consisted of inpatient stays, emergency department visits, general and vision 
related office visits, glaucoma diagnostic tests, glaucoma surgeries, and medica-
tions. Paired t-tests were used to compare baseline and follow-up costs. RESULTS: 
8,575 patients were identified as having newly diagnosed glaucoma in 2011. Mean 
glaucoma specific baseline costs were $107 (95% CI: $102, $112) and follow-up 
costs were $487 (95% CI: $475, $498); resulting in a 4.6-fold increase from baseline 
(p ≤ 0.001). 41% of follow-up glaucoma costs were due to glaucoma medications. 
Mean overall healthcare costs at baseline were $5,405 (95% CI: $5,122, $5,688) and at 
follow-up were $7,106 (95% CI: $6,677, $7,534); resulting in a 1.3-fold increase from 
baseline (p ≤ 0.001). 23.2% of follow-up total healthcare costs were due to medica-
tions. CONCLUSIONS: Glaucoma specific and overall healthcare costs significantly 
increase after glaucoma diagnosis for patients who are commercially insured.
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OBJECTIVES: The objective of this study is to evaluate the cost-effectiveness of 
aflibercept compared to ranibizumab for the treatment of wet age-related macular 
degeneration (wAMD) in Turkey. METHODS: A Markov model consisting of six health 
states on vision impairment as “no vision impairment; mild vision impairment; 
moderate vision impairment; severe vision impairment; total blindness; death” 
with a 20-year timeframe was adapted to the Turkish setting through an expert 
panel. Clinical transition inputs between visual acuity states and safety data were 
mainly derived from the results of Phase III VIEW-1 and VIEW-2 trials. Economic 
inputs were based on the expert opinion addressing local treatment, monitoring and 
adverse event management algorithms. The primary and secondary endpoints for 
the study were blind years and QALYs, respectively. Analyses were conducted from 
the Turkish Payer Social Security Institution perspective. All costs were calculated in 
Turkish Liras (TL) and then converted to USD using TL/USD currency rate as 2,1 (mid-
2014). RESULTS: Aflibercept was associated with 6,614 blind years and 4,805 QALYs, 
while ranibizumab was associated with 6,599 blind years and 4,810 QALYs; resulting 
in total of 0,015 more blind years and 0,005 less QALYs for aflibercept compared 
with ranibizumab in the treatment of wAMD. Total costs associated with aflibercept 
and ranibizumab were 25.954 USD and 30.311 USD respectively; resulting with a 
total of 4.357 USD less costs for aflibercept compared with ranibizumab, driven 
by savings in medication, administration and monitoring costs. CONCLUSIONS: 
Aflibercept was found as the cost-effective treatment option when compared with 
ranibizumab in the treatment of wAMD in Turkish setting. Aflibercept was associ-
ated with significant less cost leading to savings in medication, administration and 
monitoring costs; while being clinically equivalent with negligible benefits as blind 
years averted and QALYs gained in comparison with ranibizumab.
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OBJECTIVES: Routine clinical practice in UK patients with severe dry eye disease 
is a combination of artificial tears (AT) and ocular lubricant ointments. This study 
aims to assess the cost-effectiveness to the UK NHS of the addition of Ikervis® 
(Ciclosporin A; CsA) to routine practice for patients who have not adequately 
responded to therapy. METHODS: Using a Markov framework, future health effects 
and costs were modeled. Eligible patients receive six months therapy with Ikervis® 
plus AT and ocular lubricants or AT and ocular lubricants without CsA. Upon com-
pletion, those who respond sufficiently remain on CsA treatment for the dura-
tion of the response, achieving a higher quality of life (HRQoL) and lower AT use. 
Incremental cost effectiveness ratios (ICER) were expressed in GBP (£) per QALY 
gained with costs and health effects discounted at 3.5% over a lifetime time hori-
zon. Deterministic and probabilistic sensitivity analyses were employed to assess 
the effect of uncertainty on the model. Scenario analyses including less stringent 
improvement criteria, alternative approaches to deriving response stratified utility 
values and a shorter initial trial period were performed. RESULTS: Compared with 
AT alone, Ikervis® results in a lifetime cost to the UK NHS of £713 per patient, but 
offers an additional 0.04 QALYs. The ICER is £19,156/QALY gained. At a commonly 
accepted cost-effectiveness threshold of £30,000 per QALY, Ikervis® is cost-effective 
in 70.8% of simulations. Tornado analysis showed the model is most sensitive to 
the incremental benefit on patient’s long-term HRQoL associated with respond-
ing to therapy compared with non-response. CONCLUSIONS: The modelling study 
showed that from an NHS perspective, health gains can be achieved at a low cost. 
The Ikervis® ICERs are well below the NICE’s commonly accepted cost-effectiveness 
threshold of £30,000/QALY gained, indicating that Ikervis® in the target patient 
population would represent a cost-effective intervention in the UK.
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OBJECTIVES: To check prescribing pattern for glaucoma and to design a treatment 
guideline for POAG that is more cost effective from the perspective of a third party 
payer than the current practice based on real world evidence METHODS: A retrospec-
tive descriptive study of glaucoma patients was carried out with the aid of data col-
lection form. The prices (95% CL) of antiglaucoma drugs were estimated from hospital 
price list and the 5 nearby community pharmacies. Eighty randomly selected case 
notes of glaucoma patients on therapy for at least 3 months were studied. Data col-
lected were the demographics and diagnosis, IOP per month and the drugs prescribed. 
A Stochastic Monte model based on the outcome and cost was constructed with the 
aid of vanguard studio 5.0 (Cary, North Carolina, USA). The outcome of the therapy 
which was entered as the proportion of patients whose IOPs were normal, reduced 
or either increased or unchanged per month of treatment. Sensitivity analysis was 
conducted by varying the input data by ±50%. RESULTS: The proportion of patients 
that IOP was checked regularly was low 26.76% .The commonly prescribed drugs 
were the beta blockers and carbonic anhydrase inhibitors. The current practice will 
cost USD430.86 (NGN 77,783.76) per patient per annum whereas the proposed guide-
line that result in improved outcome will cost USD 44.10 (NGN7, 953.12). Treatment 
guideline is absent in Standard treatment guideline of Nigeria CONCLUSIONS: The 
patients that IOP was checked regularly were low and multi therapy was prescribed 
at onset with the Beta blockers plus Carbonic anhydrase inhibitors. A cost savings of 
NGN69, 830.64 will be obtained by the proposed guideline for POAG per patient per 
annum thus it could be adopted after evaluation at several sites
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relative to ranibizumab and dexamethasone. Total costs associated with afliber-
cept, ranibizumab and dexamethasone were 4.260 USD, 5.219 USD and 1.631 USD 
respectively, resulting for the cost of aflibercept treatment being 959 USD lower 
compared to ranibizumab and 2.629 USD higher compared to dexamethasone. 
Aflibercept was dominant over ranibizumab. The ICER for aflibercept as compared 
to dexamethasone was calculated as 7.144 USD/QALY. CONCLUSIONS: For the 
treatment of CRVO in Turkish setting, aflibercept was found to be the dominant 
treatment option when compared with ranibizumab while being more effective 
and less costly. Compared with dexamethasone aflibercept was found as cost-
effective with an ICER of 7.144 USD, well below the willingness-to-pay threshold 
(GDP per capita „Ÿ 10.782 USD) for Turkey.
PSS19
coSt-EffEctivEnESS of SEcukinumab comParEd to currEnt 
trEatmEntS for thE trEatmEnt of modEratE to SEvErE PlaquE 
PSoriaSiS in canada
Lee A.1, Gregory V.2, Gu Q.3, Becker D.L.1, Barbeau M.2
1Optum, Burlington, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 
3Optum, Waltham, MA, USA
OBJECTIVES: To assess the cost-effectiveness of secukinumab versus current 
therapies for plaque psoriasis in adults from the Canadian healthcare perspec-
tive. METHODS: A Markov model was designed to determine the cost-effectiveness 
of secukinumab 300mg for moderate to severe plaque psoriasis over a 10-year hori-
zon versus secukinumab 150mg, adalimumab, etanercept, infliximab, ustekinumab 
(45mg or 90mg), and standard of care (oral systemics, topicals, and phototherapy, 
SoC). Year 1 of the model consisted of 4-week cycles with 4 Psoriasis Area and 
Severity Index (PASI) response level-based health-states (PASI ≥ 90, 75-89, 50-74, 
and < 50). Years 2-10 used annual cycles, with 3 health-states (PASI ≥ 75, PASI <75, 
and death).  Decisions to switch to SoC were made at week 12 and 52, then annually. 
Efficacy data from a network meta-analysis informed first-year model transitions. 
Resource use, costs, and utilities were collected from clinical trials, published lit-
erature, expert opinion, and standard Canadian sources. RESULTS: The order of 
treatments by increasing quality-adjusted life years (QALYs) were: SoC, etanercept, 
adalimumab, ustekinumab 45mg, secukinumab 150mg, ustekinumab 90mg, secuki-
numab 300mg, and infliximab. The cost-effectiveness frontier showed etanercept 
was strongly dominated, while adalimumab, ustekinumab 45mg, secukinumab 
150mg and ustekinumab 90mg were weakly dominated by secukinumab 300mg. 
The ICER for secukinumab 300mg versus SoC was $87,368/QALY gained. The ICER for 
infliximab versus secukinumab 300mg was $1,039,403/QALY gained. Deterministic 
sensitivity analyses indicated the results are most sensitive to time horizon, cost 
of biologics, and utility values. The probabilistic sensitivity analysis demonstrated 
that at a willingness-to-pay threshold of ~$90,000/QALY, secukinumab 300mg has 
the highest probability of being the cost-effective option. CONCLUSIONS: For adults 
with moderate to severe plaque psoriasis, secukinumab 300mg was associated with 
increased QALYs at a lower incremental cost compared to etanercept, adalimumab, 
ustekinumab and secukinumab 150mg. For each QALY gained versus SoC, treatment 
with secukinumab costed an additional $87,368.
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OBJECTIVES: To report the cost per outcome of a robust model to deliver glaucoma 
examinations to older Philadelphians at community centers. METHODS: The cost-
outcome analysis was performed taking a health system perspective, with outcome 
defined as diagnostic yield (cases of glaucoma detected and cases of any ocular dis-
ease detected). Costs included supplies (slit lamp, visual field machine, handheld 
fundus camera, laptops, medical and office supplies), travel (van rental, fuel, main-
tenance, personnel mileage reimbursements), and personnel time (for examination, 
travel to sites, training, and supervision). Personnel time was captured by time and 
motion data collected during site visits. Costs of community health workers and 
medical assistants were based on regional 2013 US Bureau of Labor and Statistics (BLS) 
wage rates, and ophthalmologist wages were based on 2013 NIH salary cap. Wage rates 
for project supervisors were assumed to be 25% more than a medical assistant. Fringe 
benefits were added to all wage costs at 31% (BLS). RESULTS: 1649 participants were 
examined from 2012-2013, of whom 68% were females, 70% were African-Americans, 
and the mean age was 69 (SD 11). The mean total examination time was 56 minutes 
(SD 4). Visual field and physician consult were the most time-consuming steps (11-13 
minutes each). Glaucoma and angle closure represented 17% of the 2197 diagnoses 
made. Other diagnoses made included glaucoma suspect (16%), cataracts (52%), dia-
betic retinopathy (2%), and macular degeneration (1%). Examination and staff travel 
were the largest components of total costs at $67,018 and $24,340, respectively. The 
total program cost was $229,082 ($139/participant). The cost/case of glaucoma diag-
nosis (confirmed, suspected or angle-closure) was $550. The cost/case to detect any 
ocular disease was $104. CONCLUSIONS: The cost to deliver glaucoma examinations 
through this program is relatively low in relation to its diagnostic yield, however 
opportunities exist to improve efficiency of examination and travel.
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